DK2314321T3 - Formuleringer, der omfatter antisense-nukleotider til connexiner - Google Patents
Formuleringer, der omfatter antisense-nukleotider til connexinerInfo
- Publication number
- DK2314321T3 DK2314321T3 DK10013180.4T DK10013180T DK2314321T3 DK 2314321 T3 DK2314321 T3 DK 2314321T3 DK 10013180 T DK10013180 T DK 10013180T DK 2314321 T3 DK2314321 T3 DK 2314321T3
- Authority
- DK
- Denmark
- Prior art keywords
- connexins
- formulations
- reduction
- antisense nucleotides
- connexin
- Prior art date
Links
- 102000010970 Connexin Human genes 0.000 title abstract 3
- 108050001175 Connexin Proteins 0.000 title abstract 3
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000003716 rejuvenation Effects 0.000 abstract 1
- 230000036573 scar formation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000008719 thickening Effects 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ33392899 | 1999-01-27 | ||
NZ50019099 | 1999-10-07 | ||
EP05016736A EP1621212B1 (en) | 1999-01-27 | 2000-01-27 | Formulations comprising antisense nucleotides to connexins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2314321T3 true DK2314321T3 (da) | 2014-09-08 |
Family
ID=26652011
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10013180.4T DK2314321T3 (da) | 1999-01-27 | 2000-01-27 | Formuleringer, der omfatter antisense-nukleotider til connexiner |
DK00901236T DK1146908T3 (da) | 1999-01-27 | 2000-01-27 | Formuleringer omfattende antisense-nukleotider mod connexiner |
DK05016736.0T DK1621212T3 (da) | 1999-01-27 | 2000-01-27 | Formuleringer omfattende antisense-nukleotider til connexiner |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00901236T DK1146908T3 (da) | 1999-01-27 | 2000-01-27 | Formuleringer omfattende antisense-nukleotider mod connexiner |
DK05016736.0T DK1621212T3 (da) | 1999-01-27 | 2000-01-27 | Formuleringer omfattende antisense-nukleotider til connexiner |
Country Status (13)
Country | Link |
---|---|
US (11) | US7098190B1 (da) |
EP (3) | EP2314321B1 (da) |
JP (4) | JP4994533B2 (da) |
AT (2) | ATE300959T1 (da) |
AU (1) | AU776512B2 (da) |
CA (2) | CA2730386C (da) |
CY (2) | CY1112557T1 (da) |
DE (1) | DE60021700T2 (da) |
DK (3) | DK2314321T3 (da) |
ES (3) | ES2498745T3 (da) |
NZ (1) | NZ513154A (da) |
PT (3) | PT2314321E (da) |
WO (1) | WO2000044409A1 (da) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5991308A (ja) * | 1982-11-16 | 1984-05-26 | Kawasaki Heavy Ind Ltd | 平面の検出方法 |
JP4994533B2 (ja) * | 1999-01-27 | 2012-08-08 | デイビツド・エル・ベツカー | コネキシンに対するアンチセンスヌクレオチドを含む配合物 |
EP1197553A1 (en) * | 2000-10-12 | 2002-04-17 | A3D GmbH, Antisense Design & Drug Development | Antisense nucleic acid against alphaV integrin |
US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
AU2004294824A1 (en) | 2003-12-03 | 2005-06-16 | Coda Therapeutics (Nz) Ltd | Antisense compounds targeted to connexins and methods of use thereof |
US9408381B2 (en) | 2004-12-21 | 2016-08-09 | Musc Foundation For Research Development | Alpha Connexin c-Terminal (ACT) peptides for use in transplant |
RU2438696C2 (ru) | 2004-12-21 | 2012-01-10 | Маск Фаундейшн Фор Рисерч Дивелопмент | Композиции и способы, используемые для ускорения заживления ран и регенерации тканей |
EP2662088A3 (en) * | 2005-02-03 | 2014-02-19 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
WO2007055224A1 (ja) * | 2005-11-08 | 2007-05-18 | Kansai Technology Licensing Organization Co., Ltd. | 角膜疾患治療剤 |
CN103301475B (zh) | 2005-12-28 | 2016-08-03 | 斯克里普斯研究所 | 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用 |
JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
EP2091557A2 (en) | 2006-11-15 | 2009-08-26 | Coda Therapeutics, INC. | Improved methods and compositions for wound healing |
CN101835476B (zh) * | 2006-12-11 | 2016-08-17 | 科达治疗公司 | 作为受损伤口愈合组合物的抗连接蛋白多核苷酸 |
AU2014204482B2 (en) * | 2006-12-11 | 2016-07-07 | Coda Therapeutics, Inc. | Anticonnexin polynucleotides as impaired wound healing compositions |
DK2166845T3 (da) * | 2007-06-21 | 2016-02-01 | Musc Found For Res Dev | Alfa-connexin-c-terminale (act)-peptider til behandling af aldersrelateret makuladegeneration |
AU2008306455C1 (en) | 2007-10-03 | 2014-04-17 | Quark Pharmaceuticals, Inc. | Novel siRNA structures |
EP2628747A1 (en) | 2007-12-11 | 2013-08-21 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
CN102920996A (zh) * | 2007-12-11 | 2013-02-13 | 科达治疗公司 | 受损伤口愈合的药物组合物 |
EP2238250B1 (en) * | 2007-12-21 | 2017-07-19 | CoDa Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides, peptides or antibodies for the treatment of orthopedic conditions |
JP2011507599A (ja) * | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 改良医療デバイス |
US20110092449A1 (en) * | 2007-12-21 | 2011-04-21 | Bradford James Duft | Treatment of fibrotic conditions |
AU2008343839A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions |
EP2237786A2 (en) | 2007-12-21 | 2010-10-13 | Coda Therapeutics, Inc. | Use of inhibitors of connexin43 for treatment of fibrotic conditions |
EP2252320A2 (en) * | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides and peptides for the treatment of abnormal or excessive scars |
AU2008343758A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
EP2242844A2 (en) * | 2007-12-21 | 2010-10-27 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions |
WO2009085273A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
WO2009097077A2 (en) * | 2008-01-07 | 2009-08-06 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
AU2009293658A1 (en) | 2008-09-22 | 2010-03-25 | James Cardia | Reduced size self-delivering RNAi compounds |
JP6128732B2 (ja) | 2008-10-03 | 2017-05-17 | クルナ・インコーポレーテッド | アポリポタンパク質−a1に対する天然アンチセンス転写物の抑制によるアポリポタンパク質−a1関連疾患の治療 |
KR101761424B1 (ko) | 2008-12-04 | 2017-07-26 | 큐알엔에이, 인크. | Vegf에 대한 천연 안티센스 전사체의 억제에 의해 맥관 내피 성장 인자(vegf) 관련된 질환의 치료 |
RU2620970C2 (ru) | 2008-12-04 | 2017-05-30 | КьюРНА,Инк., | Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро |
CN102361985B (zh) | 2008-12-04 | 2017-06-20 | 库尔纳公司 | 通过抑制肿瘤抑制基因的天然反义转录物***抑制基因相关性疾病 |
US8669941B2 (en) * | 2009-01-05 | 2014-03-11 | Nuance Communications, Inc. | Method and apparatus for text entry |
ES2560107T3 (es) | 2009-02-12 | 2016-02-17 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF |
CA2755409C (en) | 2009-03-16 | 2019-04-30 | Joseph Collard | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
CA2755404C (en) | 2009-03-17 | 2020-03-24 | Joseph Collard | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
CN106237345A (zh) | 2009-05-06 | 2016-12-21 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
US20120046236A1 (en) | 2009-05-06 | 2012-02-23 | Opko Curna Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
CA3185821A1 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
CA2762369C (en) | 2009-05-18 | 2021-12-28 | Joseph Collard | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
ES2618576T3 (es) | 2009-05-28 | 2017-06-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico |
EP2443237B1 (en) | 2009-06-16 | 2017-02-22 | CuRNA, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
CN102612560B (zh) | 2009-06-16 | 2017-10-17 | 库尔纳公司 | 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病 |
US8859515B2 (en) | 2009-06-24 | 2014-10-14 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2 |
CN102482672B (zh) | 2009-06-26 | 2016-11-09 | 库尔纳公司 | 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病 |
KR101801407B1 (ko) | 2009-07-24 | 2017-11-24 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료 |
CA2769665A1 (en) | 2009-08-05 | 2011-02-10 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
US9044493B2 (en) | 2009-08-11 | 2015-06-02 | Curna, Inc. | Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin |
KR101805213B1 (ko) | 2009-08-21 | 2017-12-06 | 큐알엔에이, 인크. | Chip에 대한 천연 안티센스 전사체의 억제에 의한 “hsp70-상호작용 단백질(chip)의 c-말단” 관련된 질환의 치료 |
JP5964232B2 (ja) | 2009-08-25 | 2016-08-03 | カッパーアールエヌエー,インコーポレイテッド | ‘iqモチーフ含有gtpアーゼ活性化タンパク質’(iqgap)に対する天然アンチセンス転写産物の阻害によるiqgap関連疾患の治療 |
CA2775111C (en) | 2009-09-25 | 2019-12-31 | Opko Curna, Llc | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
KR101823702B1 (ko) | 2009-12-16 | 2018-01-30 | 큐알엔에이, 인크. | 막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료 |
RU2609631C2 (ru) | 2009-12-23 | 2017-02-02 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста гепатоцитов (фрг), посредством ингибирования природного антисмыслового транскрипта к фрг |
KR101793753B1 (ko) | 2009-12-23 | 2017-11-03 | 큐알엔에이, 인크. | 커플링방지 단백질 2(ucp2)에 대한 천연 안티센스 전사체의 저해에 의한 ucp2 관련 질환의 치료 |
US8921334B2 (en) | 2009-12-29 | 2014-12-30 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1 |
RU2611186C2 (ru) | 2009-12-29 | 2017-02-21 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63 |
JP6083735B2 (ja) | 2009-12-31 | 2017-02-22 | カッパーアールエヌエー,インコーポレイテッド | インスリン受容体基質2(irs2)および転写因子3(tfe3)に対する天然アンチセンス転写物の阻害によるインスリン受容体基質2(irs2)関連疾患の治療 |
JP5886757B2 (ja) | 2010-01-04 | 2016-03-16 | カッパーアールエヌエー,インコーポレイテッド | インターフェロン調節因子8(irf8)に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子8(irf8)関連疾患の治療 |
RU2612161C2 (ru) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы |
KR101854926B1 (ko) | 2010-01-11 | 2018-05-04 | 큐알엔에이, 인크. | 성 호르몬 결합 글로불린 (shbg)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (shbg) 관련된 질환의 치료 |
CA2786568A1 (en) | 2010-01-25 | 2011-07-28 | Curna, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
CA2790506A1 (en) | 2010-02-22 | 2011-08-25 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
CN105131067B (zh) | 2010-03-24 | 2019-02-19 | 雷克西制药公司 | 皮肤与纤维化症候中的rna干扰 |
CA2795145C (en) | 2010-04-02 | 2019-01-22 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
WO2011127337A2 (en) | 2010-04-09 | 2011-10-13 | Opko Curna Llc | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
JP2013525483A (ja) | 2010-05-03 | 2013-06-20 | カッパーアールエヌエー,インコーポレイテッド | サーチュイン(sirt)に対する天然アンチセンス転写物の阻害によるサーチュイン(sirt)関連疾患の治療 |
TWI586356B (zh) | 2010-05-14 | 2017-06-11 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
EP2576783B1 (en) | 2010-05-26 | 2017-11-29 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
RU2620978C2 (ru) | 2010-05-26 | 2017-05-30 | Курна, Инк. | Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra |
EP2585596B1 (en) | 2010-06-23 | 2020-12-30 | CuRNA, Inc. | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
RU2611190C2 (ru) | 2010-07-14 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных с геном dlg, путем ингибирования природного антисмыслового транскрипта гена dlg |
EP2625274B1 (en) | 2010-10-06 | 2017-07-19 | CuRNA, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
EP2630241B1 (en) | 2010-10-22 | 2018-10-17 | CuRNA, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
WO2012071238A2 (en) | 2010-11-23 | 2012-05-31 | Opko Curna Llc | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
CA2838588C (en) | 2011-06-09 | 2021-09-14 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
WO2013036403A1 (en) | 2011-09-06 | 2013-03-14 | Curna, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
US9308163B2 (en) | 2012-02-15 | 2016-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating and preventing diseases and disorders of the central nervous system |
RU2657535C2 (ru) | 2012-03-01 | 2018-06-14 | Ферстстринг Рисерч, Инк. | Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act) |
US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US20140274872A1 (en) * | 2013-03-15 | 2014-09-18 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
WO2013148736A1 (en) | 2012-03-27 | 2013-10-03 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
EP2970978A4 (en) * | 2013-03-11 | 2016-11-02 | Univ North Carolina | COMPOSITIONS AND METHODS OF TESTING FOR O-LINKED N-ACETYLGLUCOSAMINE TRANSFERASE AND PROMOTING WOUND HEALING |
US9156896B2 (en) | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
CA2932753A1 (en) * | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
WO2015130840A2 (en) * | 2014-02-25 | 2015-09-03 | Coda Therapeutics, Inc. | Treatment of resistant lesions |
WO2015191795A1 (en) * | 2014-06-12 | 2015-12-17 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
CN114010788A (zh) | 2014-08-22 | 2022-02-08 | 奥克兰联合服务有限公司 | 通道调节剂 |
EP3188799B1 (en) | 2014-09-05 | 2022-07-06 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
CN109071642B (zh) * | 2016-02-26 | 2022-08-09 | 德克萨斯大学体系董事会 | 连接蛋白(Cx)43半通道结合抗体及其用途 |
CA3061738A1 (en) | 2017-04-28 | 2018-11-01 | Auckland Uniservices Limited | Methods of treatment and novel constructs |
EP3685824A1 (en) * | 2019-01-25 | 2020-07-29 | Breitenbronn-Consulting GbR | Composition for administering and releasing oligonucleotides |
WO2023219655A1 (en) * | 2022-05-13 | 2023-11-16 | University Of Utah Research Foundation | Gja1-20k to limited cardiac arrhythmias |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425930D0 (en) | 1994-12-22 | 1995-02-22 | Procter & Gamble | Silicone compositions |
AU1846297A (en) * | 1996-01-31 | 1997-08-22 | Regents Of The University Of California, The | Method for inhibiting tumor cell growth |
US6489460B1 (en) * | 1996-03-07 | 2002-12-03 | Eisai Company, Ltd. | Cloned DNA encoding mammalian occludins |
WO1998002150A1 (en) * | 1996-07-17 | 1998-01-22 | Medtronic, Inc. | System for genetically treating cardiac conduction disturbances |
EP0950060A4 (en) * | 1996-12-02 | 2000-07-05 | Dyad Pharmaceutical Corp | COUNTERSTRAIN INHIBITION OF HUMAN ADHESION MOLECULES |
CA2313348A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Soluble inhibitors of vascular endothelial growth factor and use thereof |
JP4994533B2 (ja) | 1999-01-27 | 2012-08-08 | デイビツド・エル・ベツカー | コネキシンに対するアンチセンスヌクレオチドを含む配合物 |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
-
2000
- 2000-01-27 JP JP2000595711A patent/JP4994533B2/ja not_active Expired - Lifetime
- 2000-01-27 CA CA2730386A patent/CA2730386C/en not_active Expired - Fee Related
- 2000-01-27 DK DK10013180.4T patent/DK2314321T3/da active
- 2000-01-27 AU AU21193/00A patent/AU776512B2/en not_active Ceased
- 2000-01-27 AT AT00901236T patent/ATE300959T1/de active
- 2000-01-27 NZ NZ513154A patent/NZ513154A/xx not_active IP Right Cessation
- 2000-01-27 EP EP10013180.4A patent/EP2314321B1/en not_active Expired - Lifetime
- 2000-01-27 PT PT100131804T patent/PT2314321E/pt unknown
- 2000-01-27 DK DK00901236T patent/DK1146908T3/da active
- 2000-01-27 PT PT05016736T patent/PT1621212E/pt unknown
- 2000-01-27 EP EP00901236A patent/EP1146908B1/en not_active Expired - Lifetime
- 2000-01-27 WO PCT/GB2000/000238 patent/WO2000044409A1/en active IP Right Grant
- 2000-01-27 PT PT00901236T patent/PT1146908E/pt unknown
- 2000-01-27 ES ES10013180.4T patent/ES2498745T3/es not_active Expired - Lifetime
- 2000-01-27 AT AT05016736T patent/ATE533515T1/de active
- 2000-01-27 EP EP05016736A patent/EP1621212B1/en not_active Expired - Lifetime
- 2000-01-27 DK DK05016736.0T patent/DK1621212T3/da active
- 2000-01-27 DE DE60021700T patent/DE60021700T2/de not_active Expired - Lifetime
- 2000-01-27 CA CA2361251A patent/CA2361251C/en not_active Expired - Fee Related
- 2000-01-27 ES ES00901236T patent/ES2245638T3/es not_active Expired - Lifetime
- 2000-01-27 ES ES05016736T patent/ES2377749T3/es not_active Expired - Lifetime
- 2000-01-27 US US09/890,363 patent/US7098190B1/en not_active Expired - Lifetime
-
2006
- 2006-06-05 US US11/447,599 patent/US20070037765A1/en not_active Abandoned
- 2006-08-25 US US11/510,280 patent/US7615540B2/en not_active Expired - Fee Related
- 2006-08-25 US US11/510,496 patent/US7919474B2/en not_active Expired - Fee Related
- 2006-08-25 US US11/510,498 patent/US7879811B2/en not_active Expired - Fee Related
- 2006-08-29 US US11/512,730 patent/US20070072819A1/en not_active Abandoned
- 2006-08-29 US US11/512,725 patent/US20080249041A1/en not_active Abandoned
- 2006-08-29 US US11/512,735 patent/US7902164B2/en not_active Expired - Fee Related
- 2006-08-29 US US11/512,728 patent/US20070066555A1/en not_active Abandoned
-
2009
- 2009-11-30 US US12/592,668 patent/US8314074B2/en not_active Expired - Fee Related
-
2011
- 2011-08-19 JP JP2011179832A patent/JP2012041342A/ja active Pending
-
2012
- 2012-02-09 CY CY20121100139T patent/CY1112557T1/el unknown
- 2012-11-19 US US13/681,383 patent/US9193754B2/en not_active Expired - Fee Related
-
2013
- 2013-01-30 JP JP2013015172A patent/JP5736397B2/ja not_active Expired - Lifetime
- 2013-01-30 JP JP2013015171A patent/JP5705890B2/ja not_active Expired - Lifetime
-
2014
- 2014-09-03 CY CY20141100703T patent/CY1115521T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2314321T3 (da) | Formuleringer, der omfatter antisense-nukleotider til connexiner | |
EP1041880A4 (en) | ADMINISTRATION OF ARGININE TO OBTAIN A WELLBEING EFFECT | |
MY135988A (en) | Additive for improving the water resistance of cosmetic or dermatological formulations | |
CA2404810A1 (en) | Topical composition having undifferentiated plant seed cells and method for using same | |
DE69724647D1 (de) | Acyclovirhaltige antiherpesarzneistift zur topischen anwendung | |
DE60115618D1 (de) | Verwendung von kosmetische und pharmazeutische zubereitungen enthaltend 2-decarboxy-2-phosphino prostaglandinderivate | |
WO2000078341A8 (en) | A method for the prophylaxis and/or treatment of medical disorders | |
PT784481E (pt) | Formulacoes para cicatrizacao de feridas contendo fibronectina do plasma humano | |
AU2001240940A1 (en) | Cosmetic and dermatological composition for psoriatic skin, scalp treatment and care | |
DK1009425T3 (da) | Anvendelse af latens-associeret-peptid til fremstilling af et medikament til forøgelse af sårheling | |
MXPA02012075A (es) | Composicion para mediar el dolor y aparato y metodo para utilizarla. | |
FR2865651B1 (fr) | Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale | |
EP0471135B1 (en) | Composition for the promotion of hair growth | |
BR0116293A (pt) | Composição tópica, e, método para prevenir, melhorar ou tratar a hiperpigmentação da pele | |
ES2176495T3 (es) | Utilizacion de un antagonista de la bradiquinina, destinada a inducir y/o estimular el crecimiento de los cabellos y/o frenar su caida. | |
IT1258069B (it) | Composizione per uso topico avente attivita' di stimolo per la ricrescita, di rinvigorimento, di prevenzione dell'ingrigimento e di ripigmentazione naturale dei capelli | |
EP1557163A4 (en) | THERAPEUTIC AGENT FOR CONTRACTING MUCOSAL TISSUE, METHOD FOR TREATING DISEASES ASSOCIATED WITH MUCOSAL TISSUES, INJECTOR AND THERAPEUTIC KIT | |
IE810489L (en) | Composition for topical application | |
WO1994004184A3 (en) | Method of decreasing cutaneous senescence | |
WO1996001100A3 (de) | Hydrogel für die applikation von therapeutischen und/oder kosmetischen wirkstoffen an die haut | |
BR0011980A (pt) | Composiçao cosmética; e uso de uma composição | |
ATE219369T1 (de) | Anticellulitiszusammensetzung und ihre verwendung | |
RU93002420A (ru) | Способ лечения раны | |
WO2000002601A3 (en) | Transdermal delivery system | |
WO2002030443A3 (en) | Regulation of human skin healing |